{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Patients with different disease relapses was determined according to current clinical standards based on the disease. For example, AML or MDS relapse is determined by a bone marrow biopsy. Multiple myeloma relapse requires a number of labs and/or biopsy to diagnose such as SPEP, UPEP, immunofixation, serum and urine light chains. In lymphoma disease is followed using CT and/or PET scans.","groups":[{"description":"1.7 mg/kg/d thymoglobulin IV d-9 to -7","id":"OG000","title":"A:Thymoglobulin: 1.7 mg/kg/Day"},{"description":"2.5 mg/kg/d thymoglobulin IV d-9 to d-7","id":"OG001","title":"B:Thymoglobulin: 2.5 mg/kg/Day"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 year relapse rate (%)","title":"Relapse","type":"SECONDARY","unitOfMeasure":"Percent patients relapsing"}